Winter 2025

Co-op

Immunology

Posted on 9/10/2025

Moderna

Moderna

5,001-10,000 employees

Develops mRNA-based medicines for health

No salary listed

No H1B Sponsorship

Cambridge, MA, USA

In Person

70% in-office work required.

Category
Lab & Research (1)
Required Skills
Word/Pages/Docs
Data Analysis
Excel/Numbers/Sheets
PowerPoint/Keynote/Slides
Requirements
  • Currently enrolled in an undergraduate degree in biomedical sciences Biology, Chemistry, Biochemistry, Microbiology, or Molecular Biology.
  • Basic knowledge of basic lab procedures (such as pipetting) required
  • Completed foundational biology courses such as cell biology, biochemistry or laboratory techniques in biology
  • Basic proficiency in Microsoft Office (Excel, Word, PowerPoint)
  • Candidates must already hold work authorization in US and be able to maintain that status without the need for future sponsorship.
Responsibilities
  • Gaining proficiency in multiple relevant serological techniques.
  • Generation of high-quality data and data analysis skills using data analysis software like MS Excel and GraphPad Prism.
  • Regularly presenting data in team meetings to improve data presentation abilities.
  • Learning to interpret complex datasets, which are critical skills in research.
  • Understanding of the pre-clinical vaccine development process and reading relevant literature in the field of vaccinology, immunology as well as infectious diseases.
  • Additional duties as may be assigned from time to time.
Desired Qualifications
  • Technical experience in any of the following areas desired: cell/tissue culture, transfections, protein detection methods (e.g., MSD, ELISA, Luminex), molecular biology techniques (e.g., PCR, DNA/RNA extractions), assay development and troubleshooting.
  • Prior co-op or internship experience is preferred but not required.

Moderna develops medicines built on messenger RNA (mRNA). Its products use mRNA delivered into cells to instruct them to produce specific proteins that can prevent or treat disease, with vaccines being a primary example. In practice, a dose delivers engineered mRNA into the body, cells translate it into a target protein, and the immune system responds or the protein modulates biology to combat disease. Moderna differentiates itself through its focus on building a whole mRNA medicines platform and in-house capabilities for designing, manufacturing, and scaling mRNA therapies, including rapid development and large-scale production. Its goal is to create a new category of medicines based on mRNA that can improve how diseases are discovered, developed, and treated, ultimately improving patient outcomes.

Company Size

5,001-10,000

Company Stage

IPO

Headquarters

Cambridge, Massachusetts

Founded

2010

Simplify Jobs

Simplify's Take

What believers are saying

  • Q1 2026 revenue surges 260% to $389M from UK COVID partnership, guiding 10% full-year growth.
  • Phase 3 INTerpath-009 trial tests mRNA-4157 plus Keytruda in 680 NSCLC patients post-resection.
  • Hantavirus vaccine collaboration with US Army boosts pandemic preparedness amid MV Hondius outbreak.

What critics are saying

  • Pfizer's Abrysvo captures 45% flu market share, blocking mRNA-1010 pre-August 2026 launch.
  • $950M Arbutus-Genevant settlement drains 13% cash, forcing norovirus pipeline cuts by 2027.
  • Intismeran Phase 3 lung trial fails endpoints, collapsing $3.2B 2029 oncology revenue in 2028.

What makes Moderna unique

  • Moderna pioneers individualized mRNA neoantigen therapies like mRNA-4157 for personalized cancer vaccines.
  • Intismeran autogene with Keytruda shows 49% reduced recurrence risk in melanoma at five years.
  • mCOMBRIAX becomes world's first EU-approved flu-COVID combination vaccine for adults over 50.

Help us improve and share your feedback! Did you find this helpful?

Benefits

Health Insurance

Dental Insurance

Vision Insurance

Life Insurance

Disability Insurance

Health Savings Account/Flexible Spending Account

Unlimited Paid Time Off

Paid Vacation

Paid Sick Leave

Paid Holidays

Sabbatical Leave

Hybrid Work Options

401(k) Company Match

Parental Leave

Family Planning Benefits

Fertility Treatment Support

Adoption Assistance

Wellness Program

Mental Health Support

Phone/Internet Stipend

Home Office Stipend

Growth & Insights and Company News

Headcount

6 month growth

0%

1 year growth

0%

2 year growth

1%
Logicity
Apr 11th, 2026
The 'V' Word: Why Moderna is Ditching 'Vaccine' for its Cancer Breakthrough.

The 'V' Word: Why Moderna is Ditching 'Vaccine' for its Cancer Breakthrough. Moderna is rebranding its cancer treatment, a promising mRNA-based therapy, to distance itself from vaccine skepticism. This move has sparked debate among medical professionals and raises questions about transparency in clinical trials. Can a simple name change impact the future of cancer treatment? Key takeaways. * Moderna's cancer treatment uses mRNA technology to target specific cancer cells * The company has rebranded its treatment as 'individualized neoantigen therapy' to avoid vaccine skepticism * Medical professionals are divided on the impact of this name change on patient trust and transparency * The Science Behind mRNA Therapy * Moderna and Merck Team Up to Take on Cancer * The 'V' Word Dilemma: Why Moderna is Ditching 'Vaccine' * What the Experts Think: Reactions to Moderna's Rebranding * The Future of Cancer Treatment: Implications and Next Steps * Conclusion: The Road Ahead for Moderna's Cancer Breakthrough The Science Behind mRNA Therapy. Imagine a treatment that can specifically target and kill cancer cells, while leaving healthy cells intact. This is the promise of mRNA therapy, which uses genetic code to program the immune system to attack cancer cells. * mRNA therapy works by sequencing a patient's cancer cells to identify unique molecules, called neoantigens * These neoantigens are then used to create a personalized treatment that instructs the immune system to attack cancer cells Moderna and Merck Team Up to Take on Cancer. Moderna has partnered with Merck to develop its mRNA-based cancer treatment, with impressive results in clinical trials. But as the company moves forward, it's facing a new challenge: vaccine skepticism. * Moderna and Merck have shown that their treatment can halve the chance of cancer recurrence in patients with the deadliest form of skin cancer * The partnership has led to a rebranding of the treatment as 'individualized neoantigen therapy', a move that's sparked debate among medical professionals The 'V' Word Dilemma: Why Moderna is Ditching 'Vaccine' In an effort to distance itself from vaccine controversy, Moderna has stopped using the term 'vaccine' to describe its cancer treatment. But is this move a smart PR strategy, or a recipe for confusion? * Moderna's CEO has said that the rebranding is intended to 'better describe the goal of the program' * However, some medical professionals argue that the change could raise questions about transparency and patient trust What the Experts Think: Reactions to Moderna's Rebranding. Logicity Pvt Ltd spoke to medical professionals and experts in the field to get their take on Moderna's decision to rebrand its cancer treatment. Here's what they had to say. * Some experts, like Ryan Sullivan, a physician at Massachusetts General Hospital, are concerned that the name change could impact patient trust and transparency * Others, like Lillian Siu, a medical oncologist at the Princess Margaret Cancer Centre, believe that the move is a necessary step to avoid vaccine skepticism The Future of Cancer Treatment: Implications and Next Steps. As Moderna moves forward with its rebranded cancer treatment, the company faces a complex landscape of regulatory hurdles, patient trust, and public perception. What does the future hold for this promising therapy? * The success of Moderna's treatment could pave the way for a new generation of cancer therapies * However, the company must navigate a complex regulatory environment and address concerns about transparency and patient trust Conclusion: The Road Ahead for Moderna's Cancer Breakthrough. As the debate around Moderna's rebranding continues, one thing is clear: the future of cancer treatment is complex and multifaceted. What's next for this promising therapy, and how will it impact the lives of patients around the world? * Moderna's treatment has the potential to revolutionize cancer care, but it must navigate a complex landscape of regulatory hurdles and public perception * The company's decision to rebrand its treatment as 'individualized neoantigen therapy' is just the beginning of a larger conversation about transparency, trust, and the future of medicine "Vaccines are maybe a dirty word nowadays, but we still believe in the science and harnessing our immune system to not only fight infections, but hopefully to also fight... cancers" - Kyle Holen, head of Moderna's cancer program "There is some concern that there will be patients who decline to treat their cancer because it is a vaccine" - Ryan Sullivan, physician at Massachusetts General Hospital Final thoughts. As Logicity Pvt Ltd look to the future of cancer treatment, it's clear that Moderna's rebranding is just the beginning of a larger conversation about transparency, trust, and the role of language in shaping its perceptions of medicine. Will the company's move pay off, or will it spark more controversy? Only time will tell, but one thing is certain: the future of cancer care is complex, multifaceted, and full of promise. Sources & credits. Huma Shazia Senior AI & Tech Writer

MedWatch
Apr 9th, 2026
IO Biotech founder after bankruptcy: "our work is far from wasted"

IO Biotech founder after bankruptcy: "our work is far from wasted" The founder and CEO denies that funds have been wasted. IO Biotech's technology lives on with competitors such as moderna, which, according to Mai-Britt Zocca, has copied the company's core program. 9 April 2026at 15:21 Since its founding in 2015 and up until its recent bankruptcy, investors have poured well over DKK 2bn (USD 313m) into the biotech company IO Biotech, but even though the company has now collapsed, that money has not been wasted, according to founder and CEO Mai-Britt Zocca. Try MedWatch for 14 days - and get access to all content. * Continues as a recurring subscription and is billed annually. Can be terminated after 5 months of subscription with 1 month's notice at the end of a month. Minimum price is up to €539.58 excl. VAT corresponding to 7 months of subscription. Right of withdrawal under the Consumer Contracts Act. Read more here. ** Continues as a recurring subscription for 3 months at a time. Minimum price €286.00 excl. VAT. Can be terminated with 1 month's notice at the end of a 3-month period. Right of withdrawal under the Consumer Contracts Act. Read more here.

StockStory
Apr 3rd, 2026
2 S&P 500 stocks with Exciting potential and 1 We ignore.

2 S&P 500 stocks with Exciting potential and 1 We ignore. Radek strnad /. April 2, 2026 The S&P 500 (^GSPC) is home to the biggest and most well-known companies in the market, making it a go-to index for investors seeking stability. But not all large-cap stocks are created equal - some are struggling with slowing growth, declining margins, or increased competition. Some large-cap stocks are past their peak, and StockStory is here to help you separate the winners from the laggards. Keeping that in mind, here are two S&P 500 stocks leading the market forward and one best left off your watchlist. One stock to sell: Moderna (MRNA). Market Cap: $19.51 billion Rising to global prominence during the COVID-19 pandemic with one of the first effective vaccines, Moderna (NASDAQ:MRNA) develops messenger RNA (mRNA) medicines that direct the body's cells to produce proteins with therapeutic or preventive benefits for various diseases. Why Do We Avoid MRNA? * Customers postponed purchases of its products and services this cycle as its revenue declined by 46.7% annually over the last two years * Earnings per share fell by 30.2% annually over the last five years while its revenue grew, showing its incremental sales were much less profitable * Free cash flow margin dropped by 178.4 percentage points over the last five years, implying the company became more capital intensive as competition picked up Two stocks to buy: AMD (AMD). Market Cap: $354.6 billion Founded in 1969 by a group of former Fairchild semiconductor executives led by Jerry Sanders, Advanced Micro Devices (NASDAQ:AMD) is one of the leading designers of computer processors and graphics chips used in PCs and data centers. Why Are We Bullish on AMD? * Annual revenue growth of 28.8% over the past five years was outstanding, reflecting market share gains this cycle * Exciting sales outlook for the upcoming 12 months calls for 34.8% growth, an acceleration from its two-year trend * Earnings per share have comfortably outperformed the peer group average over the last five years, increasing by 26.4% annually AMD's stock price of $217.20 implies a valuation ratio of 31.7x forward P/E. Is now the right time to buy? Find out in our full research report, it's free. Texas Pacific Land (TPL). Market Cap: $30.63 billion One of America's largest private landowners with roughly 868,000 acres in the Permian Basin, Texas Pacific Land (NYSE:TPL) owns land in West Texas and earns revenue from oil and gas royalties, water services, and land leases. Why Is TPL a Top Pick? * Annual revenue growth of 26.2% over the past ten years was outstanding, reflecting market share gains this cycle * Highly-profitable operating model results in strong unit economics and a best-in-class gross margin of 95% * TPL is a free cash flow machine with the flexibility to invest in growth initiatives or return capital to shareholders At $444.10 per share, Texas Pacific Land trades at 32.8x forward EV-to-EBITDA. Is now the time to initiate a position? See for yourself in our in-depth research report, it's free. Stocks We like even more. ONE MORE THING: Top 6 Stocks for This Week. This market is separating quality stocks from expensive ones fast. AI taking down whole sectors with no warning. In a rotation this fast, you need more than a list of good companies. Our AI system flagged Palantir before it ran 1,662%. AppLovin before it ran 753%. Nvidia before it ran 1,178%. Each week it produces 6 new names that pass the same tests. Get Our Top 6 Stocks for Free HERE. Stocks that made our list in 2020 include now familiar names such as Nvidia (+1,326% between June 2020 and June 2025) as well as under-the-radar businesses like the once-small-cap company Comfort Systems (+782% five-year return). Find your next big winner with StockStory today.

Yahoo Finance
Apr 1st, 2026
Moderna settles patent dispute and shifts to cancer therapy as analysts see 71% upside

Moderna has raised investor attention following a patent dispute settlement and its pivot toward individualised cancer therapies. Trading at $50.80, the stock has posted a 72% 90-day return and 87% one-year total shareholder return, though it remains down 67% over three years. Despite reporting a $2.8 billion loss, the leading valuation thesis argues Moderna is 71% undervalued, with a fair value estimate of $175. This view emphasises the company's reinvestment of pandemic windfall profits into its mRNA platform and pipeline whilst maintaining low debt levels. The company currently trades below book value, with its valuation dependent on whether its late-stage pipeline, recurring vaccine revenue and future oncology products can generate sustained cash flows beyond its COVID-19 success.

GlobalData
Mar 27th, 2026
Recordati sizes up €10.9bn CVC capital acquisition offer.

Recordati sizes up €10.9bn CVC capital acquisition offer. If Recordati accepts CVC's offer, the company will delist from the Italian Stock Exchange. Italian pharmaceutical company, Recordati, has confirmed that it's weighing an acquisition offer from private equity manager, CVC, which is looking to solidify its controlling stake in the company. If Recordati greenlights this deal, CVC would pay €52 ($60) per share for the remaining 48.2% of the former company's shares available on the Italian Stock Exchange - potentially setting CVC back by €10.9bn ($12.6bn). While Recordati noted it has "not yet reviewed the indication of interest within its corporate bodies" for this deal, the company already has strong ties with CVC, as the firm previously acquired a controlling stake in Recordati by buying 51.8% of its stock for €3.03bn in 2018. Recordati, which celebrates its 100th birthday this year, is a global pharmaceutical group focused on primary and secondary care, as well as rare diseases within the areas of haematological oncology, endocrinology and metabolic health. The pharma company has several portfolio products on the market, including its best-selling Cushing's disease therapy, Isturisa (osilodrostat), for which an analyst consensus estimation by GlobalData projects sales of $967m in 2031. Recordati also recently added the cold agglutinin disease (CAD) medicine, Enjaymo (sutimlimab), to its treatment arsenal. The Italian pharma acquired the global rights to this drug from Sanofi for $825m upfront in 2024. Meanwhile, the company has also partnered with mRNA specialist Moderna to develop a propionic acidaemia therapy, mRNA-3927, which is currently in global Phase I/II trials. Recordati's financials are looking positive, as the company's net revenue climbed 11.8% to €2.6bn in 2025. The strong performance of the company's rare disease drugs primarily drove its growth in 2025, with revenues in this area ballooning by 29.7% compared with 2024. M&A surges ahead of Q1 close. CVC's proposed takeover bid comes amid a flurry of pharma M&A deals announced over the past week, as big players in the sector look to fortify their pipelines in preparation for the looming patent expiries soon to hit their portfolios. Today (27 March), Novartis announced it will be acquiring Excellergy for up to $3bn, thus absorbing the company's half-life extended, high-affinity anti-IgE antibody called EXL-111, which is currently in Phase I clinical trials. Earlier this week, MSD (Merck & Co) handed over $6.7bn to buy Terns Pharmaceuticals - a deal valuation that some analysts believe does not fully capture the potential of TERN-701, its BCR-ABL1 tyrosine kinase inhibitor (TKI). On 24 March, Gilead made its first moves in the T-cell engager (TCE) market with its $2.2bn acquisition of Ouro Medicines, which could see the company team up with Galapagos to develop Ouro's lead asset, gamgertamig. According to an analysis from GlobalData, the uptick in pharma deal value observed in 2025 signals renewed optimism for pharmaceutical M&A activity, but acquirers are being more selective by concentrating their investments into a smaller number of high-value deals. GlobalData is the parent company of Pharmaceutical Technology. Give your business an edge with its leading industry insights.

INACTIVE